Microcystic Adnexal Carcinoma

Microcystic Adnexal Carcinoma

No Results

No Results

processing….

Microcystic adnexal carcinoma (MAC) is a rare, malignant appendage tumor commonly classified as a low-grade sweat gland carcinoma that typically occurs on the head and neck, particularly the central face. Microcystic adnexal carcinoma shows aggressive local invasion with rare reports of lymph node metastases. [1] The image below depicts MAC on the left upper cutaneous lip.

Microcystic adnexal carcinoma (MAC) is a rare, malignant appendage tumor commonly classified as a low-grade sweat gland carcinoma that typically occurs on the head and neck, particularly the central face. Goldstein et al [2] described the first series in 1982, emphasizing the importance of its distinction from the benign histologic mimics, such as syringoma, desmoplastic trichoepithelioma, and trichoadenoma. 

Despite subsequent widespread recognition of MAC as a discrete clinicopathologic entity, its precise relationship to and histologic discrimination from other putative locally aggressive sweat gland carcinomas (reported under a variety of names, including sclerosing sweat duct carcinoma, syringoid eccrine carcinoma, syringomatous carcinoma, and eccrine epithelioma) remains unresolved and has provoked considerable nosologic and diagnostic confusion. The authors regard MAC as synonymous with group 1 sclerosing sweat duct carcinomas as described by Cooper et al. [3] In addition, the tumor described as syringomatous adenoma of the nipple or sclerosing MAC of the oral cavity (also known as MAC-like carcinomas arising in the mucosal head and neck) is regarded by some authorities as MAC.

Little information is available on the molecular pathophysiology of microcystic adnexal carcinoma (MAC), although a genetic role is plausible. A case of MAC occurring in siblings further supports this possibility. [4] In one report using cytogenetic and fluorescence in situ hybridization, a deletion on arm 6q (q23q25) was found, which is a deletion found in other malignant salivary gland tumors. [5] DNA sequencing techniques have also discovered mutations in TP53 (found on chromosome 17), chromosomal losses in cyclin-dependent kinase inhibitor 2A (CDKN2A) (found on chromosome 9), and cyclin-dependent kinase inhibitor 2B (CDKN2B) (also found on chromosome 9) in a case of metastatic MAC. [6]

Furthermore, the differentiation pathway of MAC has provoked considerable debate. Goldstein et al [2] initially suggested that it showed dual pilar (the superficially located keratocysts resembling follicular infundibula) and eccrine differentiation. Others have supported this notion, noting, in particular, that the keratocysts often expressed pilar-type keratins and that occasionally, trichohyalin granules are present. However, some authors have suggested that MAC shows only eccrine differentiation. [7]

More recently, based on the ontogenetic relationship between hair follicles and apocrine glands, MACs have been theorized to display folliculoapocrine or sometimes folliculosebaceous-apocrine differentiation rather than folliculoeccrine differentiation. [1] Support for this premise is provided by occasional cases showing focal apocrine decapitation secretion and the demonstration of sebaceous features in some tumors. [8]

Moreover, the term “sclerosing microcystic adenocarcinoma” or “MAC-like carcinomas arising in the mucosal head and neck” has also been proposed for MAC arising specifically on mucosal surfaces, owing to the lack of adnexal structures in these areas as a potential source of tumor derivation. [9] However, differences may be explained by a single-cell origin, likely found in all locations (ie, eccrine), capable of variable differentiation with a potential to display eccrine, follicular, and apocrine features. Alternatively, more than one cell line (ie, salivary, eccrine, apocrine, adnexal epithelium) could also be capable of developing into MAC, where each cell line may or may not display eccrine, follicular, or apocrine features, but uniformly demonstrates ductal differentiation common to all MACs.

In the end, there appears to be a spectrum of histopathologic presentations of MAC, in which derivation could arise from various glandular and/or adnexal origins and differentiation being influenced by endogenous/genetic factors that have yet to be definitively determined.

Approximately 19.5% (14 of 84) to 50% (5 of 10) of microcystic adnexal carcinoma (MAC) patients have had treatment with radiation therapy for a previous condition. [1, 4, 10, 11, 12] The average latency period is 30 years.

Long-term UV exposure has also been postulated as a predisposing factor for MAC, especially in view of its predilection for sun-exposed sites (ie, favoring the left side of the face, owing to suspected sun exposure while driving) and the skin of white persons. [13]

In persons of African American origin, in whom UV sun damage already plays a lesser role in cutaneous malignancy, one lesion occurred on the vulva of an African American woman [14] and multiple lesions arose on the trunk and extremities (with sparing of the face) of an African American man. [15] However, other reported cases in African Americans have occurred on the scalp [16, 17, 18] and upper cutaneous lip, [19] where sun exposure is expected. One case in a 6-year-old African American girl occurred on the left preauricular area, an area of known sun exposure, [20] but the age of onset would not suggest long-term UV light as a cause.

Its occurrence in sun-protected areas of whites [21] also suggests that UV exposure may not be the ultimate cause of MAC, but its predominant emergence on sun-exposed areas may indeed suggest a role.

Microcystic adnexal carcinoma (MAC) is a rare tumor, with only slightly more than 300 cases reported worldwide. [15] Thomas et al [22] reported a mean number of 1.63 cases per year in a rural northeastern area of the United States.

Most cases (90%) of microcystic adnexal carcinoma (MAC) occur in whites, but it may occur in persons of other races such as Latinos and Asians. [23, 21, 24] Fifty-two cases have been reported in Japan. [25, 26] In African Americans, 10 cases in total have been reported in 9 patients. [14, 15, 16, 17, 18, 19, 20, 23] The overall clinical behavior of MAC appears to be similar in all races.

No significant sexual predilection is reported, although some studies suggest a slight female predominance. [4, 13, 21, 27]

The age range is broad and has been reported from birth [28, 29] to age 90 years. [30] Most lesions manifest in the fifth to seventh decade of life. [4, 22, 21, 30] Median age is 68 years. [21]

Overall, the prognosis is good, especially when margin-control techniques such as Mohs micrographic surgery (MMS) are used, with a modest tendency for recurrence and a very low rate of metastases. Ten-year survival of patients with microcystic adnexal carcinoma (MAC) is equivalent to other patients of similar age without MAC. [21]

The largest series of cases reports an overall (combining results from simple excision and MMS) 10-year recurrence rate of 18%. Others have reported a 12% recurrence rate at mean follow-up of 39 months. [22] Recurrence in one case occurred 30 years after initial resection, making routine clinical follow up necessary. [31]

Although microcystic adnexal carcinoma is considered a nonmetastasizing tumor, rare reports detail histologically confirmed lymphatic spread. Of the more than 300 reported cases of MAC, only 10 have been metastatic. [6, 32, 33, 34, 35, 36, 37, 38, 39, 40]

Two deaths have been attributed to metastatic MAC. One patient presented with mediastinal lymphadenopathy and later died of the disease. However, no histologic evidence from the lymph nodes confirmed the cause of death. [38] The other death occurred from a MAC of the right-upper eyebrow that led to perineural spread though the orbit with central nervous system dissemination. [37] In another reported case of distant metastatic disease, the patient eventually died of aspiration pneumonia, not from the MAC itself. [39]

Morbidity is high because of the deeply infiltrating nature of the tumor, which can invade into bone, muscle, blood vessels, cartilage, and nerves. In one study, the mean clinical lesion size was 3 cm2, but the final defect size was 18 cm2, highlighting its occult extension. [22] Exquisitely rare orbital extension can occur, and a primary orbital presentation has also been reported. [41]

Mortality from metastatic disease is rare, with only six local [32, 33, 34, 35, 36, 37] and four distant metastases reported. [6, 38, 39, 40] Local metastatic disease, in most cases, may be occult contiguous extension along neurovasculature bundles. [35, 36, 37] Considering that more than 300 cases have been reported in the medical literature worldwide, [15] only two deaths have been attributed to MAC, [19, 37] both due to metastatic disease.

Of possible relation, Fernandez-Figueras et al reported a case of a high-grade carcinosarcoma with an architectural pattern similar to MAC but also exhibiting nuclear pleomorphism, hyperchromasia, and large nucleoli histologically. The patient developed metastatic lung disease from the tumor and died within 6 months. [42] The authors further noted histologic high-grade features in their case that were similar to other cases reported with metastatic disease, [19, 36, 39] and they suggested this may be an indicator for more aggressive disease. Whether the carcinomatous portion of this particular tumor represents an aggressive undefined adnexal carcinoma with an architectural pattern similar to MAC, a morphological variant of MAC with high-grade histologic features or even a squamous cell carcinoma with MAC-like differentiation, remains unknown.

Gordon S, Fischer C, Martin A, Rosman IS, Council ML. Microcystic Adnexal Carcinoma: A Review of the Literature. Dermatol Surg. 2017 Aug. 43 (8):1012-1016. [Medline].

Goldstein DJ, Barr RJ, Santa Cruz DJ. Microcystic adnexal carcinoma: a distinct clinicopathologic entity. Cancer. 1982 Aug 1. 50(3):566-72. [Medline].

Cooper PH, Mills SE. Microcystic adnexal carcinoma. J Am Acad Dermatol. 1984 May. 10(5 Pt 2):908-14. [Medline].

Abbate M, Zeitouni NC, Seyler M, Hicks W, Loree T, Cheney RT. Clinical course, risk factors, and treatment of microcystic adnexal carcinoma: a short series report. Dermatol Surg. 2003 Oct. 29(10):1035-8. [Medline].

Wohlfahrt C, Ternesten A, Sahlin P, Islam Q, Stenman G. Cytogenetic and fluorescence in situ hybridization analyses of a microcystic adnexal carcinoma with del(6)(q23q25). Cancer Genet Cytogenet. 1997 Oct 15. 98 (2):106-10. [Medline].

Chen MB, Laber DA. Metastatic Microcystic Adnexal Carcinoma with DNA Sequencing Results and Response to Systemic Antineoplastic Chemotherapy. Anticancer Res. 2017 Sep. 37 (9):5109-5111. [Medline].

Requena L, Marquina A, Alegre V, Aliaga A, Sanchez Yus E. Sclerosing-sweat-duct (microcystic adnexal) carcinoma–a tumor from a single eccrine origin. Clin Exp Dermatol. 1990 May. 15 (3):222-4. [Medline].

Fernandez-Flores A, Llamas-Velasco M, Saus C, Patel A, Rutten A. Microcystic adnexal carcinoma with sebaceous differentiation: Three cases. J Cutan Pathol. 2018 Apr. 45 (4):290-295. [Medline].

Mills AM, Policarpio-Nicholas ML, Agaimy A, Wick MR, Mills SE. Sclerosing Microcystic Adenocarcinoma of the Head and Neck Mucosa: A Neoplasm Closely Resembling Microcystic Adnexal Carcinoma. Head Neck Pathol. 2016 Dec. 10 (4):501-508. [Medline].

Eisen DB, Zloty D. Microcystic adnexal carcinoma involving a large portion of the face: when is surgery not reasonable?. Dermatol Surg. 2005 Nov. 31(11 Pt 1):1472-7; discussion 1478. [Medline].

Antley CA, Carney M, Smoller BR. Microcystic adnexal carcinoma arising in the setting of previous radiation therapy. J Cutan Pathol. 1999 Jan. 26(1):48-50. [Medline].

Schwarze HP, Loche F, Lamant L, Kuchta J, Bazex J. Microcystic adnexal carcinoma induced by multiple radiation therapy. Int J Dermatol. 2000 May. 39(5):369-72. [Medline].

Chiller K, Passaro D, Scheuller M, Singer M, McCalmont T, Grekin RC. Microcystic adnexal carcinoma: forty-eight cases, their treatment, and their outcome. Arch Dermatol. 2000 Nov. 136(11):1355-9. [Medline].

Buhl A, Landow S, Lee YC, Holcomb K, Heilman E, Abulafia O. Microcystic adnexal carcinoma of the vulva. Gynecol Oncol. 2001 Sep. 82(3):571-4. [Medline].

Page RN, Hanggi MC, King R, Googe PB. Multiple microcystic adnexal carcinomas. Cutis. 2007 Apr. 79(4):299-303. [Medline].

Park JY, Parry EL. Microcystic adnexal carcinoma. First reported case in a black patient. Dermatol Surg. 1998 Aug. 24(8):905-7. [Medline].

Gardner ES, Goldberg LH. Neglected microcystic adnexal carcinoma: the second reported case in a black patient. Dermatol Surg. 2001 Jul. 27(7):678-80. [Medline].

Scott B, Nijhawan RI, Desman G, Johnson-Jahangir H. Microcystic Adnexal Carcinoma of the scalp in an african-american male. Dermatol Online J. 2016 Sep 15. 22 (9):[Medline].

Peterson CM, Ratz JL, Sangueza OP. Microcystic adnexal carcinoma: First reported case in an African American man. J Am Acad Dermatol. 2001 Aug. 45(2):283-5. [Medline].

Nelson PS, Bourgeois KM, Nicotri T Jr, Chiu ES, Poole JC. Sclerosing sweat duct carcinoma in a 6-year-old African American child. Pediatr Dermatol. 2008 Jan-Feb. 25(1):38-42. [Medline].

Yu JB, Blitzblau RC, Patel SC, Decker RH, Wilson LD. Surveillance, Epidemiology, and End Results (SEER) database analysis of microcystic adnexal carcinoma (sclerosing sweat duct carcinoma) of the skin. Am J Clin Oncol. 2010 Apr. 33(2):125-7. [Medline].

Thomas CJ, Wood GC, Marks VJ. Mohs micrographic surgery in the treatment of rare aggressive cutaneous tumors: the Geisinger experience. Dermatol Surg. 2007 Mar. 33(3):333-9. [Medline].

Nadiminti H, Nadiminti U, Washington C. Microcystic adnexal carcinoma in African-Americans. Dermatol Surg. 2007 Nov. 33(11):1384-7. [Medline].

Chen J, Yang S, Chen J, Liao T, Deng W, Li W. Microcystic adnexal carcinoma in a non-Caucasian patient: A case report and review of the literature. Oncol Lett. 2016 Apr. 11 (4):2471-2474. [Medline].

Murata S, Fujita S, Sugihara K, Akasu T, Moriya Y, Nakanishi Y. Sclerosing sweat duct carcinoma in the peri-anal skin: a case report. Jpn J Clin Oncol. 1997 Jun. 27(3):197-9. [Medline].

Ohtsuka H, Nagamatsu S. Microcystic adnexal carcinoma: review of 51 Japanese patients. Dermatology. 2002. 204(3):190-3. [Medline].

Friedman PM, Friedman RH, Jiang SB, Nouri K, Amonette R, Robins P. Microcystic adnexal carcinoma: collaborative series review and update. J Am Acad Dermatol. 1999 Aug. 41(2 Pt 1):225-31. [Medline].

Fu T, Clark FL, Lorenz HP, Bruckner AL. Congenital microcystic adnexal carcinoma. Arch Dermatol. 2011 Feb. 147(2):256-7. [Medline].

Smart DR, Taintor AR, Kelly ME, Lyon VB, Segura A, Jensen JN, et al. Microcystic adnexal carcinoma: the first reported congenital case. Pediatr Dermatol. 2011 Jan-Feb. 28(1):35-8. [Medline].

Cooper PH. Carcinomas of sweat glands. Pathol Annu. 1987. 22 Pt 1:83-124. [Medline].

Burns MK, Chen SP, Goldberg LH. Microcystic adnexal carcinoma. Ten cases treated by Mohs micrographic surgery. J Dermatol Surg Oncol. 1994 Jul. 20(7):429-34. [Medline].

Bier-Laning CM, Hom DB, Gapany M, Manivel JC, Duvall AJ 3rd. Microcystic adnexal carcinoma: management options based on long-term follow-up. Laryngoscope. 1995 Nov. 105(11):1197-201. [Medline].

Kirkland PM, Solomons NB, Ratcliffe NA. Microcystic adnexal carcinoma. J Laryngol Otol. 1997 Jul. 111(7):674-5. [Medline].

Carroll P, Goldstein GD, Brown CW Jr. Metastatic microcystic adnexal carcinoma in an immunocompromised patient. Dermatol Surg. 2000 Jun. 26(6):531-4. [Medline].

Rotter N, Wagner H, Fuchshuber S, Issing WJ. Cervical metastases of microcystic adnexal carcinoma in an otherwise healthy woman. Eur Arch Otorhinolaryngol. 2003 May. 260(5):254-7. [Medline].

Ban M, Sugie S, Kamiya H, Kitajima Y. Microcystic adnexal carcinoma with lymph node metastasis. Dermatology. 2003. 207(4):395-7. [Medline].

Gomez-Maestra MJ, Espana-Gregori E, Avino-Martinez JA, Mancheno-Franch N, Pena S. Brainstem and cavernous sinus metastases arising from a microcystic adnexal carcinoma of the eyebrow by perineural spreading. Can J Ophthalmol. 2009 Jun. 44(3):e17-8. [Medline].

Yugueros P, Kane WJ, Goellner JR. Sweat gland carcinoma: a clinicopathologic analysis of an expanded series in a single institution. Plast Reconstr Surg. 1998 Sep. 102(3):705-10. [Medline].

Ohta M, Hiramoto M, Ohtsuka H. Metastatic microcystic adnexal carcinoma: an autopsy case. Dermatol Surg. 2004 Jun. 30(6):957-60. [Medline].

Gabillot-Carré M, Weill F, Mamelle G, et al. Microcystic adnexal carcinoma: report of seven cases including one with lung metastasis. Dermatology. 2006. 212(3):221-8. [Medline].

Wu-Chen WY, Weng CY, Rajan KD, Eberhart C, Miller NR. Unusual presentation of primary orbital microcystic adnexal carcinoma. J Neuroophthalmol. 2011 Jun. 31(2):147-50. [Medline].

Fernández-Figueras MT, Montero MA, Admella J, de la Torre N, Quer A, Ariza A. High (nuclear) grade adnexal carcinoma with microcystic adnexal carcinoma-like structural features. Am J Dermatopathol. 2006 Aug. 28(4):346-51. [Medline].

Mueller SK, Iro H, Lell M, Seifert F, Bohr C, Scherl C, et al. Microcystic adnexal carcinoma (MAC)-like squamous cell carcinoma as a differential diagnosis to Bell´s palsy: review of guidelines for refractory facial nerve palsy. J Otolaryngol Head Neck Surg. 2017 Jan 5. 46 (1):1. [Medline].

Wong LK, Kereke AR, Wright AE, Vyas KS. Microcystic Adnexal Carcinoma of the Nipple. Wounds. 2018 Jun. 30 (6):E65-E67. [Medline].

Marchitelli C, Peremateu MS, Pasetti D, Sluga MC, Wernicke A, Gogorza S. Microcystic Adnexal Vulvar Carcinoma: A Case Report. J Low Genit Tract Dis. 2017 Jan. 21 (1):e5-e7. [Medline].

Astorino S, Carelli G, Dattola A, Pasquini P. Microcystic adnexal carcinoma of the skin in atypical site (pubic region): clinical and dermatoscopic features. G Ital Dermatol Venereol. 2018 Sep 20. [Medline].

Weissferdt A, Moran CA. Microcystic squamous cell carcinoma of the lung: a clinicopathologic study of three cases. Am J Clin Pathol. 2011 Sep. 136(3):436-41. [Medline].

Schaller J, Rytina E, Rütten A, Hendricks C, Ha T, Requena L. Sweat duct proliferation associated with aggregates of elastic tissue and atrophodermia vermiculata: a simulator of microcystic adnexal carcinoma. Report of two cases. J Cutan Pathol. 2010 Sep. 37(9):1002-9. [Medline].

Tawfik AM, Kreft A, Wagner W, Vogl TJ. MRI of a microcystic adnexal carcinoma of the skin mimicking a fibrous tumour: case report and literature review. Br J Radiol. 2011 Jun. 84(1002):e114-7. [Medline].

Inskip M, Magee J. Microcystic adnexal carcinoma of the cheek-a case report with dermatoscopy and dermatopathology. Dermatol Pract Concept. 2015 Jan. 5 (1):43-6. [Medline].

Calderón-Castrat X, Román-Curto C, Santos-Briz A, Fernández-López E. Microcystic adnexal carcinoma mimicking basal cell carcinoma. JAAD Case Rep. 2017 Nov. 3 (6):492-494. [Medline].

Bush JW, Gru AA, Wick MR. Immunoreactivity for Sox10 in Basaloid Neoplasms of The Skin. Appl Immunohistochem Mol Morphol. 2018 Dec 7. [Medline].

Alawi SA, Batz S, Röwert-Huber J, Fluhr JW, Lademann J, Ulrich M. Correlation of optical coherence tomography and histology in microcystic adnexal carcinoma: a case report. Skin Res Technol. 2014 Feb 17. [Medline].

Giambrone D, Salvaggio C, Victor FC, Rao BK. Microcystic Adnexal Carcinoma Detected by Reflectance Confocal Microscopy. Dermatol Surg. 2016 Jan. 42 (1):126-7. [Medline].

Sirikanjanapong S, Seymour AW, Amin B. Cytologic features of microcystic adnexal carcinoma. Cytojournal. 2011 Mar 3. 8:5. [Medline]. [Full Text].

Leibovitch I, Huilgol SC, Selva D, Lun K, Richards S, Paver R. Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery. J Am Acad Dermatol. 2005 Feb. 52(2):295-300. [Medline].

Cooper PH, Mills SE, Leonard DD, Santa Cruz DJ, Headington JT, Barr RJ, et al. Sclerosing sweat duct (syringomatous) carcinoma. Am J Surg Pathol. 1985 Jun. 9(6):422-33. [Medline].

McCalmont TH, Ye J. Eosinophils as a clue to the diagnosis of microcystic adnexal carcinoma. J Cutan Pathol. 2011 Nov. 38(11):849, 850-2. [Medline].

LeBoit PE, Sexton M. Microcystic adnexal carcinoma of the skin. A reappraisal of the differentiation and differential diagnosis of an underrecognized neoplasm. J Am Acad Dermatol. 1993 Oct. 29(4):609-18. [Medline].

Ibrahim YL, Lambert S, Kazakov DV, Kaya G. An Unusual Morphological Presentation of Cutaneous Squamous Cell Carcinoma Mimicking Microcystic Adnexal Carcinoma: A Diagnostic Pitfall. Dermatopathology (Basel). 2018 Apr-Jun. 5 (2):64-68. [Medline].

Kazakov DV, Kacerovska D, Michal M. Microcystic adnexal carcinoma with multiple areas of follicular differentiation toward germinative cells and specific follicular stroma (trichoblastomatous areas). Am J Dermatopathol. 2011 Jun. 33(4):e47-9. [Medline].

Llamas-Velasco M, Pérez-Gónzalez YC, Bosch-Príncep R, Fernández-Figueras MT, Rütten A. Solid carcinoma is a variant of microcystic adnexal carcinoma: A 14-case series. J Cutan Pathol. 2018 Dec. 45 (12):897-904. [Medline].

Wang SQ, Goldberg LH, Nemeth A. The merits of adding toluidine blue-stained slides in Mohs surgery in the treatment of a microcystic adnexal carcinoma. J Am Acad Dermatol. 2007 Jun. 56(6):1067-9. [Medline].

Vidal CI, Goldberg M, Burstein DE, Emanuel HJ, Emanuel PO. p63 Immunohistochemisty Is a Useful Adjunct in Distinguishing Sclerosing Cutaneous Tumors. Am J Dermatopathol. 2010 Jan 21. [Medline].

Krahl D, Sellheyer K. p75 Neurotrophin receptor differentiates between morphoeic basal cell carcinoma and desmoplastic trichoepithelioma: insights into the histogenesis of adnexal tumours based on embryology and hair follicle biology. Br J Dermatol. 2010 Jul. 163(1):138-45. [Medline].

Jedrych J, McNiff JM. Expression of p75 neurotrophin receptor in desmoplastic trichoepithelioma, infiltrative basal cell carcinoma, and microcystic adnexal carcinoma. Am J Dermatopathol. 2013 May. 35(3):308-15. [Medline].

Hoang MP, Dresser KA, Kapur P, High WA, Mahalingam M. Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Mod Pathol. 2008 Feb. 21(2):178-85. [Medline].

Krahl D, Sellheyer K. Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma. J Cutan Pathol. 2007 Oct. 34(10):782-7. [Medline].

Bogner PN, Su LD, Fullen DR. Cluster designation 5 staining of normal and non-lymphoid neoplastic skin. J Cutan Pathol. 2005 Jan. 32(1):50-4. [Medline].

Jedrych J, Leffell D, McNiff JM. Desmoplastic trichoepithelioma with perineural involvement: a series of seven cases. J Cutan Pathol. 2012 Mar. 39(3):317-23. [Medline].

Wick MR, Cooper PH, Swanson PE, Kaye VN, Sun TT. Microcystic adnexal carcinoma. An immunohistochemical comparison with other cutaneous appendage tumors. Arch Dermatol. 1990 Feb. 126(2):189-94. [Medline].

Plaza JA, Ortega PF, Stockman DL, Suster S. Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases. J Cutan Pathol. 2010 Apr. 37(4):403-10. [Medline].

Rollins-Raval M, Chivukula M, Tseng GC, Jukic D, Dabbs DJ. An immunohistochemical panel to differentiate metastatic breast carcinoma to skin from primary sweat gland carcinomas with a review of the literature. Arch Pathol Lab Med. 2011 Aug. 135(8):975-83. [Medline].

Kavand S, Cassarino DS. “Squamoid eccrine ductal carcinoma”: an unusual low-grade case with follicular differentiation. Are these tumors squamoid variants of microcystic adnexal carcinoma?. Am J Dermatopathol. 2009 Dec. 31(8):849-52. [Medline].

Haga T, Fujimura T, Aiba S. Successful treatment of microcystic adnexal carcinoma on the philtrum with oral S-1 monotherapy. J Dermatol. 2019 Jan 21. [Medline].

Stein JM, Ormsby A, Esclamado R, Bailin P. The effect of radiation therapy on microcystic adnexal carcinoma: a case report. Head Neck. 2003 Mar. 25(3):251-4. [Medline].

Wetter R, Goldstein GD. Microcystic adnexal carcinoma: a diagnostic and therapeutic challenge. Dermatol Ther. 2008 Nov-Dec. 21(6):452-8. [Medline].

Baxi S, Deb S, Weedon D, Baumann K, Poulsen M. Microcystic adnexal carcinoma of the skin: the role of adjuvant radiotherapy. J Med Imaging Radiat Oncol. 2010 Oct. 54(5):477-82. [Medline].

Pugh TJ, Lee NY, Pacheco T, Raben D. Microcystic adnexal carcinoma of the face treated with radiation therapy: A case report and review of the literature. Head Neck. 2012 Jul. 34(7):1045-50. [Medline].

Kim LH, Teston L, Sasani S, Henderson C. Microcystic adnexal carcinoma: successful management of a large scalp lesion. J Plast Surg Hand Surg. 2014 Apr. 48(2):158-60. [Medline].

Brent AJ, Deol SS, Vaidhyanath R, Saldanha G, Sampath R. A case and literature review of orbital microcystic adnexal carcinoma. Orbit. 2018 Feb 20. 1-4. [Medline].

Mamic M, Manojlovic L, Suton P, Luksic I. Microcystic adnexal carcinoma-diagnostic criteria and therapeutic methods: case report and review of the literature. Int J Oral Maxillofac Surg. 2018 Oct. 47 (10):1258-1262. [Medline].

Gulmen S, Pullon PA. Sweat gland carcinoma of the lips. Oral Surg Oral Med Oral Pathol. 1976 May. 41(5):643-9. [Medline].

Antley CA, Carney M, Smoller BR. Microcystic adnexal carcinoma arising in the setting of previous radiation therapy. J Cutan Pathol. 1999 Jan. 26(1):48-50. [Medline].

Borenstein A, Seidman DS, Trau H, Tsur H. Microcystic adnexal carcinoma following radiotherapy in childhood. Am J Med Sci. 1991 Apr. 301(4):259-61. [Medline].

Tolkachjov SN. Adnexal Carcinomas Treated With Mohs Micrographic Surgery: A Comprehensive Review. Dermatol Surg. 2017 Oct. 43 (10):1199-1207. [Medline].

Snow S, Madjar DD, Hardy S, et al. Microcystic adnexal carcinoma: report of 13 cases and review of the literature. Dermatol Surg. 2001 Apr. 27(4):401-8. [Medline].

Khachemoune A, Olbricht SM, Johnson DS. Microcystic adnexal carcinoma: report of four cases treated with Mohs’ micrographic surgical technique. Int J Dermatol. 2005 Jun. 44(6):507-12. [Medline].

Barlow RJ, Ramnarain N, Smith N, Mayou B, Markey AC, Walker NP. Excision of selected skin tumours using Mohs’ micrographic surgery with horizontal paraffin-embedded sections. Br J Dermatol. 1996 Dec. 135(6):911-7. [Medline].

Nektarios I Lountzis, MD Consulting Staff, Advanced Dermatology Associates, Ltd, Lehigh Valley Health Network

Nektarios I Lountzis, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, American Contact Dermatitis Society, International Society of Dermatopathology

Disclosure: Nothing to disclose.

Kelley Cross Ramsauer, MD Resident Physician, Department of Dermatology, Geisinger Health System

Kelley Cross Ramsauer, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Society for Dermatologic Surgery, Gold Humanism Honor Society, Women’s Dermatologic Society

Disclosure: Nothing to disclose.

Mary Grace Petrick, MD Consulting Staff, Department of Dermatology, Geisinger Medical Center

Mary Grace Petrick, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery

Disclosure: Nothing to disclose.

Michael J Wells, MD, FAAD Dermatologic/Mohs Surgeon, The Surgery Center at Plano Dermatology

Michael J Wells, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Texas Medical Association

Disclosure: Nothing to disclose.

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Kelly M Cordoro, MD Assistant Professor of Clinical Dermatology and Pediatrics, Department of Dermatology, University of California, San Francisco School of Medicine

Kelly M Cordoro, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Medical Society of Virginia, Society for Pediatric Dermatology, Women’s Dermatologic Society, Association of Professors of Dermatology, National Psoriasis Foundation, Dermatology Foundation

Disclosure: Nothing to disclose.

Mary Farley, MD Dermatologic Surgeon/Mohs Surgeon, Anne Arundel Surgery Center

Disclosure: Nothing to disclose.

Bruce C Gee, MBBCh, MRCP Specialist Registrar, Department of Dermatology, Queen’s Medical Centre, UK

Bruce C Gee, MBBCh, MRCP is a member of the following medical societies: Royal College of Physicians

Disclosure: Nothing to disclose.

Kevin Hollowood, MD, MBBS, MRCP, FRCPath Consulting Staff, Department of Pathology, John Radcliffe Hospital of Oxford, UK

Disclosure: Nothing to disclose.

Microcystic Adnexal Carcinoma

Research & References of Microcystic Adnexal Carcinoma|A&C Accounting And Tax Services
Source